$BFRG

BullFrog AI (BFRG) announced progress in its drug discovery program for major depressive disorder with an unnamed top-five global pharmaceutical partner, identifying and prioritizing novel therapeutic targets using its AI platform. The company views this as commercial validation of its technology, though no financial terms were disclosed. BullFrog AI is also exploring drug targets for schizophrenia and bipolar disorder.

BullFrog AI Holdings (NASDAQ:BFRG) shares rose 24.57% to $0.75 in premarket trading. CEO Vininder Singh and CFO Joshua Blacher bought 75,000 and 50,000 shares respectively. The company signed a feasibility agreement with a top-5 pharma firm for depression drug targets. BFRG has a $11.19M market cap, 52-week range $0.43-$2.04, and 12-month decline of 56.20%.

Blacher Joshua (Chief Financial Officer) purchased 50,000 shares of BullFrog AI Holdings, Inc. (BFRG) at $0.53 on 2026-09-22.

Singh Vininder (Chief Executive Officer) purchased 75,000 shares of BullFrog AI Holdings, Inc. (BFRG) at $0.60 on 2026-09-22.

BullFrog AI Holdings, Inc. (BFRG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001829247 0001829247 2026-06-11 2026-06-11 0001829247 BFRG:CommonStockParValue0.00001Member 2026-06-11 2026-06-11 0001829247 BFRG:TradeableWarrantsMember 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSIO

BullFrog AI Holdings (NASDAQ: BFRG; BFRGW) said it appointed John Stewart as SVP Commercial Sales, Eric Roos as SVP Business Development & Corporate Strategy, and Tom Hazel, Ph.D., as VP Scientific Operations to execute its growth strategy for its integrated pharma AI platform. The company said the team will expand its commercial pipeline and partnerships across bfPREP, bfLEAP and bfARENAS.

Bullfrog AI Holdings Inc. (BFRG) shares surged over 152% after announcing an agreement with a major global pharmaceutical company. This collaboration will utilize Bullfrog AI's bfLEAP program to identify and prioritize novel drug targets for major depressive disorder (MDD), aiming to accelerate drug discovery and clinical development. CEO Vin Singh views the agreement as a validation of Bullfrog AI's capabilities and anticipates expanding the partnership into other R&D areas.

RedChip Companies will broadcast interviews with BullFrog AI, Inc. (Nasdaq:BFRG) and Myriad Uranium Corp. (OCTQB:MYRUF) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV this Saturday, November 29, at 7 p.m. ET. BullFrog AI's CEO will discuss their AI-driven drug development platform, highlighting recent milestones and growth potential in the biopharma R&D market. Myriad Uranium's CEO will outline the company's strategy for advancing its Copper Mountain and Red Basin uranium projects, emphasizing their significant resource estimates and market positioning amid increasing global demand for uranium.

New publication details how BullFrog Data Networks® and bfLEAP® technology address fundamental AI challenges in drug discovery and development New publication details how BullFrog Data Networks® and bfLEAP® technology address fundamental AI challenges in drug discovery and development ...

GAITHERSBURG, Md., Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- BullFrog AI Holdings, Inc.